Some of these considerations will be built into an upcoming prospective phase I/II trial evaluating newly diagnosed GBM patients, before and after treatment with standard radiation, nivolumab (anti-PD-1 mAb) and BMS986205 (IDO1 enzyme inhibitor), led by our group. The gene discussed is IDO1; the disease is glioblastoma.